Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 6:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 243 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Escitalopram Oxalate Clear all
Completed Phase 4 Interventional Results available

Dichotic Listening as a Predictor of Medication Response in Depression

NCT00404755
View directory record Official record
Conditions
Major Depressive Disorder, Dysthymia
Interventions
escitalopram, bupropion, imipramine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Oct 11, 2026, 6:12 AM EDT
Completed Phase 2 Interventional Results available

eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk

NCT04437485
View directory record Official record
Conditions
Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Type 2 Diabetes, PreDiabetes, Insulin Resistance
Interventions
Good Days Ahead (GDA), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Active Control
Behavioral · Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 11, 2026, 6:12 AM EDT
Completed Not applicable Interventional Results available

Adjunctive Treatment of Major Depression Utilizing Auricular Acupuncture

NCT02579343
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Auricular Acupuncture, Sham Auricular Acupuncture + Lexapro
Device · Drug
Lead sponsor
Florida Gulf Coast University
Other
Eligibility
18 Years to 24 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 11, 2026, 6:12 AM EDT
Not listed No phase listed Observational

Tracking Response to Antidepressants in Advance of Investigational Trials

NCT04748276
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs)
Drug
Lead sponsor
Adams Clinical
Network
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Watertown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 11, 2026, 6:12 AM EDT
Completed Phase 3 Interventional

Effects of Antidepressants on Sexual Functioning

NCT00051259
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Extended-Release Bupropion Hydrochloride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
23
States / cities
Berkeley, California • Beverly Hills, California • La Mesa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2010 · Synced Oct 11, 2026, 6:12 AM EDT
Completed Not applicable Interventional Results available

Effects of Adding Motivational Interviewing to Antidepressant Treatment for Hispanic Adults With Depression

NCT00564278
View directory record Official record
Conditions
Depression
Interventions
Standard antidepressant therapy (SADT), Motivational antidepressant therapy (MADT)
Drug · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 79 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 11, 2026, 6:12 AM EDT
Completed Phase 3 Interventional Results available

A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression

NCT02493868
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
53
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 50 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 11, 2026, 6:12 AM EDT
Completed No phase listed Observational

Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline

NCT00667121
View directory record Official record
Conditions
Breast Cancer, Depression, Hot Flashes, Psychosocial Effects of Cancer and Its Treatment
Interventions
citalopram hydrobromide, escitalopram oxalate, gabapentin, sertraline hydrochloride, tamoxifen citrate, venlafaxine, molecular genetic technique, high performance liquid chromatography, laboratory biomarker analysis, pharmacological study, adjuvant therapy
Drug · Genetic · Other + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
Indianapolis, Indiana • Baltimore, Maryland • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 11, 2026, 6:12 AM EDT
Completed Phase 2Phase 3 Interventional

Treatment of Adolescent Suicide Attempters (TASA)

NCT00080158
View directory record Official record
Conditions
Depression, Suicide, Attempted
Interventions
fluoxetine, sertraline, citalopram, escitalopram, bupropion, mirtazapine, venlafaxine, lithium, Cognitive Behavioral Therapy
Drug · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
12 Years to 18 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
6
States / cities
Baltimore, Maryland • New York, New York • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced Oct 11, 2026, 6:12 AM EDT
Completed Not applicable Interventional

A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program

NCT02297126
View directory record Official record
Conditions
Adverse Drug Reaction
Interventions
Pharmacogenetic Intervention Arm (pharmacogenetic testing)
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
4,465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 8, 2021 · Synced Oct 11, 2026, 6:12 AM EDT
Completed Phase 3 Interventional

Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder

NCT00109044
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 80 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
18
States / cities
Phoenix, Arizona • Boulder, Colorado • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Oct 11, 2026, 6:12 AM EDT
Completed Phase 4 Interventional Results available

SSRI Effects on Depression and Immunity in HIV/AIDS

NCT02620150
View directory record Official record
Conditions
Depression, HIV, AIDS
Interventions
Escitalopram, Placebo
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 11, 2026, 6:12 AM EDT
Terminated Phase 2 Interventional Results available

Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder

NCT01103180
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
Escitalopram
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 11, 2026, 6:12 AM EDT
Completed Phase 4 Interventional Results available

Cognitive-Behavioral Therapy and Escitalopram for Generalized Anxiety Disorder(GAD)

NCT00219349
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Cognitive Behavioral Therapy, escitalopram
Behavioral · Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Oct 11, 2026, 6:12 AM EDT
Completed Phase 2Phase 3 Interventional

Effects of Duloxetine vs. Escitalopram on Heart Rate Variability in Depression

NCT00215228
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
duloxetine vs. escitalopram
Drug
Lead sponsor
Duke University
Other
Eligibility
20 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 11, 2026, 6:12 AM EDT
Completed Phase 4 Interventional Results available

Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits

NCT04352101
View directory record Official record
Conditions
Major Depression
Interventions
Bupropion XL, Escitalopram
Drug
Lead sponsor
Emory University
Other
Eligibility
25 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 29, 2023 · Synced Oct 11, 2026, 6:12 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression

NCT02422186
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (New Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
65 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
15
States / cities
San Diego, California • New Haven, Connecticut • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 11, 2026, 6:12 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessing Anterior Cingulate Brain Activity in People With Late-Life Depression

NCT00926653
View directory record Official record
Conditions
Depression
Interventions
Escitalopram
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
60 Years to 85 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
White Plains, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2015 · Synced Oct 11, 2026, 6:12 AM EDT
Completed Phase 4 Interventional Results available

The ISLAND Study: InSuLa Assessed Needs for Depression

NCT02137369
View directory record Official record
Conditions
Depression
Interventions
Selective serotonin re-uptake inhibitor, Cognitive Behavioral Therapy, Combination treatment (SSRI + CBT)
Drug · Behavioral · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 60 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Oct 11, 2026, 6:12 AM EDT
Completed No phase listed Observational

Impact of Caregiver Depression on Asthma in the Child

NCT00223288
View directory record Official record
Conditions
Depressive Disorder, Major, Asthma
Interventions
Lexapro
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
175 participants
Timeline
2003 – 2006
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2011 · Synced Oct 11, 2026, 6:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Effects of Duloxetine on Norepinephrine

NCT00414323
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Duloxetine, Escitalopram, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
2
States / cities
Glendale, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2007 · Synced Oct 11, 2026, 6:12 AM EDT
Completed Phase 4 Interventional Results available

Anxiety and Depression in Epilepsy: A Treatment Study

NCT03464383
View directory record Official record
Conditions
Anxiety, Depression, Epilepsy
Interventions
Escitalopram 10mg, Referral to Psychiatry, Survey only
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 11, 2026, 6:12 AM EDT
Not listed Phase 3 Interventional

Escitalopram Combination Comparison Study for Adult Patients With Major Depressive Disorder

NCT00239954
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram
Drug
Lead sponsor
Pharmacology Research Institute
Other
Eligibility
18 Years to 80 Years
Timeline
Started 2005
U.S. locations
4
States / cities
Los Alamitos, California • Newport Beach, California • Northridge, California + 1 more
Source: ClinicalTrials.gov public record
Updated May 9, 2012 · Synced Oct 11, 2026, 6:12 AM EDT
Terminated Phase 4 Interventional Results available

Seroquel Alone Versus Seroquel With an SSRI for Depression With Psychotic Symptoms

NCT00955474
View directory record Official record
Conditions
Major Depressive Disorder With Psychotic Features
Interventions
Quetiapine, escitalopram, Sertraline, Citalopram
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Oct 11, 2026, 6:12 AM EDT